# Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

> **NCT00352066** · PHASE1 · COMPLETED · sponsor: **Avexa** · enrollment: 18 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** apricitabine

## Key facts

- **NCT ID:** NCT00352066
- **Lead sponsor:** Avexa
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2011-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352066, "Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00352066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*